William Blair research analyst Matt Phipps joined CNBC’s “Worldwide Exchange” to discuss the implications for pharmaceutical companies that have their drugs listed on Medicare’s price negotiation roster.
Equity Research
Matt Phipps Guests on CNBC
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights
Our Latest News
Inari Medical, Inc.: Initiation of Research Coverage
William Blair initiated research coverage of Inari Medical, Inc. (NARI $54.73), a medical device company that develops interventional products for patients suffering from venous diseases.
Read morePFAS Solutions (Part 2): The Potential Impact of Loper Bright on the PFAS Market
In this episode of William Blair Thinking Presents, Tim Mulrooney, group head of global services, follows up on his last episode about the PFAS market to detail how the recent Supreme Court ruling known as Loper Bright could have far-reaching implications for all types of regulations, including environmental ones like PFAS.
Listen to the podcastTrupanion, Inc.: Initiation of Research Coverage
William Blair initiated research coverage of Trupanion, Inc. (TRUP $35.31), a leader in the global pet insurance market.
Read more